Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J3120 Testosterone Enanthate Testosterone Enanthate 100 mg Hormonal Therapy Androgen No 1953 Jan 1, 1982 Jan 1, 2015 No Longer Used
NA Estradiol Estrace 0.5mg Hormonal Therapy Estrogen Yes 1998 In Use
NA Altretamine Hexalen 50 mg Chemotherapy Alkylating Agent Triazines Yes 1990 2019 In Use
NA Avapritinib Ayvakit 100mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
NA Toremifene Citrate Fareston 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
NA Cysteamine Bitartrate Procysbi 25mg, 75mg, 300mg Chemotherapy Cystine-Depleting Agent Yes 2013 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
NA isotretinoin Absorica, Amnesteem, Claravis, Myorisan, Zenatane many Hormonal Therapy Immunomodulator Retinoic Acid Derivative Yes 1982 In Use
NA Afatinib Gliotrif 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
Inavolisib Itovebi 3mg, 9mg Chemotherapy Enzyme Inhibitor PI3K⍺ Yes 2024 In Use
NA Lenalidomide Revlimid 5 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2005 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
N/A Taletrectinib IBTROZI 272mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2025 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA idelalisib Zydelig 150 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
NA ixazomib Ninlaro 2.3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
Adagrasib Krazati 200mg Immunotherapy RAS Inhibitor KrAS G12C Yes 2022 In Use
NA Aprepitant Emend 125 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Abemaciclib Verzenio 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
S0179 Megesterol Megace 20 mg Hormonal Therapy Progestin Yes 2002 In Use
NA Nintedanib Ofev 150 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.